Actual medication label and appearance may vary
Peptide Treatment
Tesamorelin
Choose a treatment option
Tesamorelin is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH). It is designed to stimulate the pituitary gland to synthesize and release the body’s natural growth hormone (GH) in a pulsatile manner. While a specific brand of Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, its use in other clinical or wellness settings is considered off-label.
Check eligibilityTesamorelin is not FDA-approved to diagnose, treat, cure, or prevent any disease, or for general anti-aging purposes.
Why it works
Key benefits
- Significant reduction in visceral (deep abdominal) adipose tissue
- Improved metabolic profiles and lipid levels
- Support for lean muscle mass and physical recovery
- Enhanced skin elasticity and potential improvements in sleep quality
Observed in clinical and wellness research. Note: Continued treatment is generally required to maintain fat-reduction benefits.*
Mechanism
How it works
Tesamorelin binds to GHRH receptors in the pituitary gland with high specificity. This stimulation triggers a natural "pulse" of growth hormone, which subsequently increases levels of Insulin-like Growth Factor-1 (IGF-1). Increased GH levels assist in lipolysis (the breakdown of fats), particularly visceral adipose tissue (deep abdominal fat), and support metabolic health and tissue repair.
Frequently asked questions
FAQs
Reductions in visceral fat are typically gradual. In clinical trials, significant changes were observed over 26 weeks. Some patients may notice initial improvements in energy or sleep within the first month. If treatment is stopped, abdominal fat levels typically return to their original state over several months.
Injection Site Reactions: Redness, itching, pain, or swelling Musculoskeletal: Joint pain, muscle aches, or stiffness Metabolic: Increases in blood sugar levels or fluid retention (swelling of hands/feet) General: Nausea, headache, or tingling sensations (paresthesia)
Before you begin
Informed Consent & Safety
Report any persistent joint pain, significant swelling, or signs of high blood sugar to your provider. Tesamorelin is contraindicated in patients with active malignancy, pregnancy, or known hypersensitivity to Mannitol. Patients with a history of cancer or diabetes must be monitored closely, as GH stimulation can affect cell growth and glucose metabolism.
Research & Studies
Evidence at a Glance
- 1.
Falutz J et al. New England Journal of Medicine (2007). Multicenter, randomized trial showing Tesamorelin significantly reduces visceral fat and improves body image.
- 2.
Mangweth-Matzek B et al. Journal of Clinical Endocrinology & Metabolism (2010). Long-term safety and efficacy data regarding GHRH analogs in fat redistribution.
- 3.
Stanley TL et al. JAMA (2014). Study on the effects of Tesamorelin on visceral fat and liver fat in patients without HIV.
- 4.
Spooner LM, Olin JL. Annals of Pharmacotherapy (2012). Detailed pharmacology of Tesamorelin as a growth hormone-releasing factor analog.
- 5.
FDA (2010). Original approval summary for Egrifta (Tesamorelin) highlighting mechanism of action and safety signals.
- 6.
Makimura H et al. J Clin Endocrinol Metab (2009). Evaluation of GHRH stimulation on GH pulsatility and IGF-1 levels in adults with abdominal obesity.
Interested in Tesamorelin?
Take a short assessment and a licensed provider will review if this treatment is right for you.
Clinical Guidance Disclaimer
The information provided in this document is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. It should never replace sound clinical judgment or personalized advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read in these materials.
Liability & Indemnification
By utilizing this information, the user acknowledges and agrees that REBL and its affiliates, providers, and staff are not liable for any direct, indirect, or consequential damages resulting from the use or misuse of the information provided herein. Any reliance on the materials contained in this document is solely at the user's own risk.
Regulatory Status
Tesamorelin is a compounded peptide prepared by licensed pharmacies. While the molecule itself has an FDA-approved indication for HIV-associated lipodystrophy, this compounded version is not FDA-approved for general wellness, fat loss in non-HIV patients, or performance enhancement.
Proprietary Rights & Use Restrictions
This document and its contents are the proprietary property of REBL. Unauthorized use, duplication, reproduction, or distribution of these materials—in whole or in part—without express written consent is strictly prohibited.